Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Eagle Pharmaceuticals
Deal Size : $17.5 million
Deal Type : Licensing Agreement
Details : With this approval, SymBio will convert its current lyophilized formulation of TREAKISYM to the new RTD liquid formulation upon launch in January 2021.
Brand Name : Treakisym
Molecule Type : Small molecule
Upfront Cash : $12.5 million
September 23, 2020
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Eagle Pharmaceuticals
Deal Size : $17.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SymBio Pharmaceuticals Limited has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion in Japan. Company plans to submit a New Drug Application for the product.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 30, 2020
Lead Product(s) : Bendamustine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
